Why does administering a COX-2 selective inhibitor, like celecoxib, reduce inflammation while increasing the risk of thrombotic events in a patient?

💡 Explanation

Selective COX-2 inhibitors disrupt the normal prostaglandin balance because they block the production of prostacyclin (PGI2), a vasodilator and inhibitor of platelet aggregation. Therefore, the relative increase in thromboxane A2, a vasoconstrictor and platelet aggregator, increases thrombotic risk rather than other prostaglandin pathways.

• Why does damaged skin sometimes develop keloid scars following wound closure, despite collagen synthesis?
• What causes increased afterload in the left ventricle due to arterial stiffness during hypertension?
• What causes lymph flow reduction during severe dehydration, impacting interstitial fluid drainage?
• Which mechanism causes increased perceived roughness while palpating skin following capsaicin exposure?
• Which consequence results when hypothalamic-pituitary axis negative repression fails?
• Why does cellular dysfunction persist after the acute phase of a concussion, despite apparent macroscopic brain recovery?